CollabRx and OncoDNA Partner in Molecular Diagnostics

CollabRx, Inc. (CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, and OncoDNA, SA, a Belgium company that provides DNA next generation sequencing (NGS) tests for clinical use in cancer, today announced a multi-year agreement to purchase CollabRx SaaS-based technology and content resources to be used in conjunction with OncoDNA's cancer mutation panels.

OncoDNA and CollabRx will develop a combined test and medical informatics solution by pairing the results of cancer mutational panels developed by OncoDNA with clinically actionable and dynamically updated knowledge provided by CollabRx. Such knowledge includes the clinical impact of specific mutational profiles and associated therapeutic strategies such as drugs and clinical trials and is supported by CollabRx's large and growing network of over 75 leading clinical practitioners in the U.S. and Europe.

BioScrip Reports Fourth Quarter 2012 Financial Results

BioScrip, Inc. (BIOS) today announced 2012 fourth quarter financial results.  Fourth quarter revenue from continuing operations was $180.7 million and the net loss from continuing operations was $1.4 million, or $0.03 per diluted share. Consolidated Adjusted EBITDA for the fourth quarter was $12.1 million, and consolidated adjusted earnings per diluted share for the fourth quarter was $0.04 per diluted share.

This quarter, the Company will also begin reporting adjusted earnings per diluted share ("Adjusted EPS"), which excludes the same elements in calculating Adjusted EBITDA (restructuring and other expenses, acquisition and integration expenses, stock-based compensation expense) as well as the impact of acquisition-related intangible amortization.  Management believes that this non-GAAP financial measure provides useful supplemental information regarding the performance of our business operations and facilitates comparisons to our historical operating results.

CardioComm Solutions Initiates U.S. Distribution of the HeartCheck (TM) PEN ECG Device

CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"), a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, today announced a distribution agreement with TAW Global. TAW Global designs and markets specialty products aimed at meeting the unique needs and demands of consumers around the world, and will be selling the HeartCheck PEN into the U.S. Market commencing immediately.

Allscripts announces fourth quarter 2012 results

Bookings grow 11.6 percent quarter-over-quarter to $180.7 million
Operating cash flow of $58.1 million for quarter; $222.6 million for full year

Allscripts Healthcare Solutions, Inc. (MDRX) today announced financial results for the three months and year ended December 31, 2012.

Fourth-Quarter Details:

• Bookings(1) of $180.7 million.  This compares with bookings of $327.4 million in the fourth quarter of 2011 and $161.9 million in the third quarter of 2012.
• GAAP revenue of $350.9 million and non-GAAP revenue of $368.0 million.  This compares with GAAP and non-GAAP revenue of $388.2 and $389.2 million, respectively, in the fourth quarter of 2011. 

  Published: 20 February 2013

  Written by Editor

  Nasdaq   Healthcare   Financial Results   Up on News   Interesting News  

  Read more: Allscripts Healthcare Solutions ( MDRX )